NICO Corporation has announced that the results from the completed ENRICH trial will be presented at the annual American Association of Neurological Surgeons (AANS) meeting (21–24 April 2023, Los Angeles, USA).
The ENRICH results were accepted as a late-breaker and will be presented during an oral plenary session on Saturday 22 April by co-lead ENRICH investigator Gustavo Pradilla (Grady Memorial Hospital, Atlanta, USA).
ENRICH was designed to evaluate the safety, efficacy and economic outcomes in intracranial haemorrhagic (ICH) stroke, comparing minimally invasive parafascicular surgery (MIPS) using NICO’s complete technology solution, comprised of BrainPath and Myriad, versus standard of care—medical management based on American Heart Association/American Stroke Association (AHA/ASA) guidelines.
As per a company press release, BrainPath was the first neurosurgery device to enable minimally disruptive, navigable, trans-sulcal access to the brain, while Myriad offers multifunctional capabilities for automated, non-ablative haemorrhage evacuation.
“The ENRICH clinical trial represents almost seven years of dedication aiming to improve clinical outcomes for those who suffer from devastating haemorrhagic strokes,” said Jim Pearson, president and CEO, NICO Corporation. “To date, there has never been a positive randomised controlled trial demonstrating the benefit of surgical evacuation of ICH, so we eagerly await the results of the ENRICH trial at AANS. We also thank the entire stroke community for their efforts in supporting the trial, especially our partner, Emory University [Atlanta, USA], the ENRICH investigators, stroke centres and coordinators, patients and caregivers for their support in delivering this scientific evidence.”
